Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2018
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 9 - Pipeline Review, H1 2018'; Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Cyclin-dependent kinase 9 (CDK9) is a cyclin-dependent kinase associated with P-TEFb. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with CDK9 and cyclin T, which suggested a possible involvement of this protein in AIDS.
The report 'Cyclin Dependent Kinase 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Hodgkin Lymphoma, Relapsed Acute Myeloid Leukemia, AIDS - Related Cancer, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Bleeding And Clotting Disorders, Blood Cancer, Cystic Fibrosis, Epstein-Barr Virus (HHV-4) Infections, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatitis B, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Laryngeal Cancer, Leukemias, Lymphoma, Mantle Cell Lymphoma, Pituitary ACTH Hypersecretion (Cushing Disease), Prostate Cancer, Pseudomonas aeruginosa Infections, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Simplexvirus (HSV) Infections, Unspecified B-Cell Lymphomas, Uterine Cancer and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 9 - Pipeline Review, H1 2018'; Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Cyclin-dependent kinase 9 (CDK9) is a cyclin-dependent kinase associated with P-TEFb. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with CDK9 and cyclin T, which suggested a possible involvement of this protein in AIDS.
The report 'Cyclin Dependent Kinase 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Hodgkin Lymphoma, Relapsed Acute Myeloid Leukemia, AIDS - Related Cancer, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Bleeding And Clotting Disorders, Blood Cancer, Cystic Fibrosis, Epstein-Barr Virus (HHV-4) Infections, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatitis B, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Laryngeal Cancer, Leukemias, Lymphoma, Mantle Cell Lymphoma, Pituitary ACTH Hypersecretion (Cushing Disease), Prostate Cancer, Pseudomonas aeruginosa Infections, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Simplexvirus (HSV) Infections, Unspecified B-Cell Lymphomas, Uterine Cancer and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)
- The report reviews Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Cyclacel Pharmaceuticals Inc
Jyant Technologies Inc
MEI Pharma Inc
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
ViroStatics srl
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
alvocidib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alvocidib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atuveciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-5576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1251152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit CDK9 for Acute Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
I-073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclin Dependent Kinase 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-1287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
Apr 16, 2018: Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Apr 13, 2018: Tolero Pharmaceuticals to Present Preclinical Data Supporting Apoptosis-Inducing Activity of Alvocidib in Acute Myeloid Leukemia
Mar 15, 2018: Phase 1 Clinical Data with Cyclacel's CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Oct 23, 2017: Tolero Pharma To Present Preclinical Data for Cancer Drug Candidate TP-1287 for Myc-dependent Triple Negative Breast Cancer
Oct 05, 2017: Tolero Pharmaceuticals to Provide Update on alvocidib at 9th International Conference on Leukemia and Hematologic Oncology
Sep 26, 2017: Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer
Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
Jun 21, 2017: Tolero Pharmaceuticals to Expand Enrollment of Phase II Study of Alvocidib in MCL-1-Dependent AML into Europe
Jun 15, 2017: Tolero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting
May 08, 2017: Tolero Pharmaceuticals Appoints Robert Imani Vice President, Drug Development
Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib at AACR 2017
Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on Alvocidib's Prodrug, TP-1287, at AACR 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Cyclacel Pharmaceuticals Inc
Jyant Technologies Inc
MEI Pharma Inc
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
ViroStatics srl
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
alvocidib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alvocidib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atuveciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-5576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1251152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit CDK9 for Acute Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
I-073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclin Dependent Kinase 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-1287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
Apr 16, 2018: Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Apr 13, 2018: Tolero Pharmaceuticals to Present Preclinical Data Supporting Apoptosis-Inducing Activity of Alvocidib in Acute Myeloid Leukemia
Mar 15, 2018: Phase 1 Clinical Data with Cyclacel's CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Oct 23, 2017: Tolero Pharma To Present Preclinical Data for Cancer Drug Candidate TP-1287 for Myc-dependent Triple Negative Breast Cancer
Oct 05, 2017: Tolero Pharmaceuticals to Provide Update on alvocidib at 9th International Conference on Leukemia and Hematologic Oncology
Sep 26, 2017: Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer
Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
Jun 21, 2017: Tolero Pharmaceuticals to Expand Enrollment of Phase II Study of Alvocidib in MCL-1-Dependent AML into Europe
Jun 15, 2017: Tolero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting
May 08, 2017: Tolero Pharmaceuticals Appoints Robert Imani Vice President, Drug Development
Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib at AACR 2017
Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on Alvocidib's Prodrug, TP-1287, at AACR 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Astex Pharmaceuticals Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Pipeline by Jyant Technologies Inc, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Tolero Pharmaceuticals Inc, H1 2018
Pipeline by Vichem Chemie Research Ltd, H1 2018
Pipeline by ViroStatics srl, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Astex Pharmaceuticals Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Pipeline by Jyant Technologies Inc, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Tolero Pharmaceuticals Inc, H1 2018
Pipeline by Vichem Chemie Research Ltd, H1 2018
Pipeline by ViroStatics srl, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Cyclacel Pharmaceuticals Inc
Jyant Technologies Inc
MEI Pharma Inc
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
ViroStatics srl
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Cyclacel Pharmaceuticals Inc
Jyant Technologies Inc
MEI Pharma Inc
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
ViroStatics srl
